Where can researchers source third-party tested CJC-1295?

Midwest Peptide supplies research-grade CJC-1295 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

CJC/Ipa Lean Mass Research | Midwest Peptide

Tesamorelin Lean Mass Research: Muscle Preservation StudiesPrev|CJC/Ipa and Sleep: Nocturnal GH Pulse ResearchNext

CJC/Ipa Lean Mass Research: Body Composition Endpoints

CJC-1295 / Ipamorelin · Published April 24, 2026 · Updated May 18, 2026 · 10 min read

Quick Answer

CJC-1295/Ipamorelin lean mass research examines body composition endpoints in rodent models, including lean tissue accretion, fat mass shifts, and muscle protein dynamics. Studies use DXA, MRI, and biomarker panels to characterize how dual GHRH/GHRP activation affects body composition. For research use only, not for human consumption.

CJC/Ipa Lean Mass Research: Body Composition Endpoints

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

Growth Hormone and Lean Mass Biology
Body Composition Measurement in Research Models
Skeletal Muscle Protein Synthesis
Muscle Fiber Cross Sectional Area
Lean Mass Preservation in Catabolic Models
Age Related Lean Mass Decline
Functional Strength Endpoints
Integration With Fat Mass Effects
Research Design Considerations
Research Peptides Referenced
Related Research Reading
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

CJC-1295 and ipamorelin lean mass research addresses the body composition effects of growth hormone secretagogue administration in preclinical models, with specific focus on the skeletal muscle and lean tissue endpoints that complement the growth hormone pulse and IGF-1 axis data covered elsewhere in the CJC-1295 / Ipamorelin Blend: What Researchers Need to Know. While the cluster documents the upstream endocrine pharmacology in detail, this article focuses on the downstream tissue level outcomes in muscle and lean compartments.

Frequently Asked Questions

What is CJC-1295 in research contexts?

CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It is studied in research models as a long-acting GHRH receptor agonist that drives pulsatile growth hormone release from the pituitary.

How is lean mass measured in CJC/Ipa rodent research?

Methods include DEXA scanning, MRI, and quantitative magnetic resonance (qMR) systems like EchoMRI. Whole-carcass dissection with separation of fat, lean, bone, and water provides ground-truth validation in terminal studies.

What body composition changes are reported with CJC/Ipa?

Rodent studies report increases in lean mass and modest reductions in adipose mass with chronic CJC/Ipa exposure, attributed to elevated GH/IGF-1 signaling effects on muscle protein synthesis and adipose lipolysis.

Is CJC-1295 approved for human use?

No. CJC-1295 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Glossary

Key terms used in this article.

GHRH: Growth hormone-releasing hormone, the hypothalamic peptide that stimulates pituitary growth hormone release.
DAC (Drug Affinity Complex): A maleimidopropionic acid linker on CJC-1295 that covalently binds serum albumin to extend half-life.
Pulsatile Release: The episodic, rhythmic secretion pattern characteristic of growth hormone from the anterior pituitary.
Pituitary Somatotroph: The anterior pituitary cell type that synthesizes and secretes growth hormone.
IGF-1: Insulin-like growth factor 1, the primary downstream mediator of growth hormone action, produced largely in the liver.
GHS-R1a: Growth hormone secretagogue receptor 1a, the ghrelin receptor through which ipamorelin signals.
GHRP: Growth hormone-releasing peptide, a class of synthetic ghrelin receptor agonists that stimulate GH release.
Ghrelin: The endogenous 28-amino-acid acylated peptide hormone that activates GHS-R1a and stimulates appetite and GH release.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. CJC-1295 and ipamorelin are intended exclusively for in vitro and preclinical animal research. They are not approved for human use, are not drugs, and should never be administered to humans.

Growth Hormone and Lean Mass Biology

Growth hormone is one of the major hormonal regulators of lean body mass. The growth hormone axis promotes protein synthesis in skeletal muscle, supports nitrogen retention, stimulates amino acid uptake into muscle cells, and promotes lipolysis in adipose tissue. The net effect of growth hormone signaling is a shift in body composition toward more lean mass and less fat mass, which is the characteristic body composition profile of growth hormone sufficiency.

The downstream mediator of many of these tissue level effects is IGF-1, produced primarily by the liver in response to growth hormone signaling and locally in muscle tissue in response to both growth hormone and mechanical loading. The IGF-1 axis article in this cluster covers the IGF-1 biology in detail. The lean mass research extends this into the specific tissue endpoints that IGF-1 signaling produces in skeletal muscle.

The Nature subject hub on muscle biology and the ScienceDirect lean body mass topic page both archive primary research on the integration of endocrine signaling with skeletal muscle biology.

Body Composition Measurement in Research Models

Body composition in rodent research is measured through several complementary methods. Dual energy X ray absorptiometry provides whole body and regional measurements of lean mass, fat mass, and bone mineral content. Magnetic resonance imaging and micro CT provide volumetric measurements with anatomical detail. Nuclear magnetic resonance based body composition analyzers provide rapid whole body measurements without anesthesia. Dissection and weighing of specific tissues provides the most direct but terminal measurements.

Published CJC-1295 and ipamorelin research has used these methods to document body composition changes over dosing periods of weeks to months. The findings document increases in lean mass and reciprocal decreases in fat mass in treated animals compared to vehicle controls. The magnitude of lean mass increase depends on the dose, the duration of treatment, and the age and baseline body composition of the animals.

The body composition data is most informative when presented as lean mass and fat mass separately rather than as total body weight alone, because a compound that increases lean mass and decreases fat mass by similar magnitudes may produce little change in total body weight while producing substantial changes in body composition. The tesamorelin lean mass article in the tesamorelin cluster documents related body composition research from a different GHRH analog perspective.

Skeletal Muscle Protein Synthesis

Growth hormone and IGF-1 promote skeletal muscle protein synthesis through activation of the mTOR signaling pathway, which is the central integrator of anabolic signals in muscle. The mTOR pathway responds to amino acid availability, insulin signaling, mechanical loading, and IGF-1 signaling among other inputs. Growth hormone secretagogue administration that elevates IGF-1 provides a sustained anabolic input through this pathway.

Published research on CJC-1295 and ipamorelin has examined muscle protein synthesis rates using isotope tracer methods that directly measure the rate of new protein incorporation into muscle tissue. The findings document increased fractional synthesis rates in treated animals compared to controls, with the magnitude of increase consistent with the elevation in circulating and local IGF-1 concentrations.

The protein synthesis effects are most prominent in fast twitch glycolytic muscle fibers, which have higher growth hormone receptor expression and IGF-1 responsiveness than slow twitch oxidative fibers. This fiber type specificity is consistent with the known biology of growth hormone axis signaling in muscle and may affect the functional consequences depending on which muscle groups and fiber types are measured.

The Cell Press journal Cell Metabolism archives primary research on muscle protein synthesis regulation.

Muscle Fiber Cross Sectional Area

Muscle fiber cross sectional area is a histological endpoint that reflects the size of individual muscle fibers and is a direct morphological indicator of muscle hypertrophy or atrophy. Growth hormone and IGF-1 signaling increase fiber cross sectional area through increased protein content per fiber.

Published CJC-1295 and ipamorelin research documents increased muscle fiber cross sectional area in treated rodents compared to controls. The increase is measurable by histomorphometric analysis of muscle cross sections stained with standard myosin heavy chain antibodies. The fiber type specific effects are consistent with the protein synthesis data, with larger relative increases in fast twitch fibers than in slow twitch fibers.

The fiber cross sectional area data provides tissue level confirmation that the systemic endocrine effects documented at the hormone and receptor level translate to morphological changes in the target tissue. This translation from endocrine pharmacology to tissue level outcomes is an important validation step for growth hormone secretagogue research.

The Wiley Online Library muscle research collection archives primary research on muscle morphometry methods.

Lean Mass Preservation in Catabolic Models

Beyond normal anabolic conditions, lean mass preservation during catabolic states is a research context where growth hormone secretagogues have been examined. Catabolic states including food restriction, immobilization, corticosteroid administration, and aging all produce lean mass loss through reduced protein synthesis and increased protein degradation. Research on whether CJC-1295 and ipamorelin can attenuate this lean mass loss provides data on the protective capacity of growth hormone axis stimulation.

Published research in food restriction models documents partial preservation of lean mass in CJC-1295 and ipamorelin treated animals compared to food restricted vehicle controls. The treated animals lose less lean mass per unit of total weight loss, which indicates a shift in the substrate being metabolized away from muscle protein and toward adipose tissue stores. This lean sparing effect is consistent with the growth hormone driven lipolysis that provides alternative fuel and reduces the need for muscle protein catabolism.

The lean mass preservation data connects to the cagrilintide weight maintenance article and the MOTS-c obesity article in adjacent clusters, where body composition during weight loss is also a research endpoint. Different compounds achieve lean sparing through different mechanisms, and comparative research across compound classes can dissect the relative contributions.

Sarcopenia, the age related decline in skeletal muscle mass and function, is associated with declining growth hormone and IGF-1 levels in aging animals. The growth hormone axis becomes less active with age, with reduced pulse amplitude, reduced frequency, and declining circulating IGF-1 concentrations. This endocrine decline contributes to the progressive lean mass loss that characterizes aging.

Research on CJC-1295 and ipamorelin in aged rodent models has examined whether restoring growth hormone pulse amplitude through secretagogue administration can attenuate age related lean mass decline. Published findings document partial restoration of lean mass and muscle fiber size in aged treated animals compared to aged vehicle controls, with the magnitude of restoration less than what is achieved in young animals.

The age related research connects to the broader aging peptide literature including the MOTS-c aging article, the NAD+ in Research: A Comprehensive Review of Nicotinamide Adenine Dinucleotide Studies, and the GHK-Cu skin aging article. Each compound addresses aging through different mechanistic entry points, and the growth hormone axis is one of the endocrine systems that declines with age and can be partially restored through pharmacological intervention.

The Frontiers in Endocrinology open access journal and the ScienceDirect sarcopenia topic page archive primary research on age related muscle biology.

Functional Strength Endpoints

Lean mass measurements are complemented by functional strength testing in research models. Grip strength testing, ex vivo muscle contractility measurements, and in vivo assessments of locomotor performance provide functional correlates of the lean mass data. A compound that increases lean mass without increasing functional performance would be less interesting than one that produces both.

Published CJC-1295 and ipamorelin research includes functional testing data that aligns with the lean mass findings. Treated animals show improved grip strength, improved maximum force production in isolated muscle preparations, and improved locomotor performance in treadmill or running wheel assessments. The functional improvements are proportionate to the lean mass increases, suggesting that the added lean mass is functionally competent rather than dysfunctional.

Integration With Fat Mass Effects

The lean mass effects of CJC-1295 and ipamorelin do not occur in isolation from the fat mass effects. Growth hormone signaling promotes lipolysis in parallel with protein synthesis, and the net body composition shift reflects both components. The tesamorelin lipolysis article covers the lipolytic biology in the context of tesamorelin, and the same mechanisms operate with CJC-1295 and ipamorelin through the shared growth hormone axis.

The simultaneous increase in lean mass and decrease in fat mass is the characteristic growth hormone body composition signature. Research designs that measure both compartments provide the full picture, and the ratio of lean mass gain to fat mass loss is an informative metric for comparing different growth hormone secretagogue protocols.

The incretin receptor agonists in the Midwest Peptide catalog also affect body composition but through different mechanisms. GLP-1 SM, GLP-2 TZ, and GLP-3 RT produce weight loss primarily through reduced food intake and altered substrate utilization, with variable effects on lean mass preservation depending on the specific compound. The GLP-3 RT lean mass article covers the lean mass perspective from the triple agonist approach.

Research Design Considerations

Lean mass research with growth hormone secretagogues requires appropriate study duration because lean mass changes develop more slowly than acute endocrine changes. Studies of less than two weeks are unlikely to detect meaningful lean mass differences. Studies of four to eight weeks provide the standard time frame for body composition endpoints. Longer studies are needed for age related endpoints.

The dietary context matters because protein availability affects the capacity for new protein synthesis. Ad libitum feeding with adequate protein supports maximal lean mass response. Protein restricted feeding limits the response regardless of the endocrine stimulus. The dietary composition should be documented and standardized across treatment groups.

Research Peptides Referenced

CJC-1295/Ipamorelin Blend 10mg, research grade GHRH/GHRP combination, third party COA
Tesamorelin 10mg, alternative GHRH analog
Tesa/Ipa 10mg Blend, alternative GHRH/GHRP combination
GLP-1 SM 20mg, lipidated GLP-1 receptor agonist
GLP-3 RT, triple incretin receptor agonist
MOTS-c 10mg, mitochondrial derived peptide

For complete sourcing details see the CJC/Ipa sourcing guide.

Within the CJC/Ipa cluster:

Related clusters:

Not for human consumption. Research use only.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

MOTS-C 10mg, 99%+ purity, COA included
Tesamorelin 10mg, 99%+ purity, COA included
NAD+ 500mg, 99%+ purity, COA included
GLP-1 SM 20mg, 99%+ purity, COA included
GHK-Cu 50mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

CJC/Ipa Lean Mass Research: Body Composition Endpoints

Frequently Asked Questions

What is CJC-1295 in research contexts?

How is lean mass measured in CJC/Ipa rodent research?

What body composition changes are reported with CJC/Ipa?

Is CJC-1295 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Growth Hormone and Lean Mass Biology

Body Composition Measurement in Research Models

Skeletal Muscle Protein Synthesis

Muscle Fiber Cross Sectional Area

Lean Mass Preservation in Catabolic Models

Functional Strength Endpoints

Integration With Fat Mass Effects

Research Design Considerations

Research Peptides Referenced

Ready to Start Your Research?

Where can researchers source third-party tested CJC-1295?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

CJC/Ipa Lean Mass Research: Body Composition Endpoints

Frequently Asked Questions

What is CJC-1295 in research contexts?

How is lean mass measured in CJC/Ipa rodent research?

What body composition changes are reported with CJC/Ipa?

Is CJC-1295 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Growth Hormone and Lean Mass Biology

Body Composition Measurement in Research Models

Skeletal Muscle Protein Synthesis

Muscle Fiber Cross Sectional Area

Lean Mass Preservation in Catabolic Models

Age Related Lean Mass Decline

Functional Strength Endpoints

Integration With Fat Mass Effects

Research Design Considerations

Research Peptides Referenced

Related Research Reading

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested CJC-1295?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?